Amicus Therapeutics — Q1 2025 Earnings Presentation
27 slides from Amicus Therapeutics's earnings presentation, May 1, 2025
Slide 1: 1Q25 Results Conference Call & Webcast
AT T H E F O R E F R O N T O F THERAPIES FOR RARE DISEASES 1Q25 Results Conference Call & Webcast May 1, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the prospects and timing of the potential regulatory and pricing approval of our products, commercialization plans, manufacturing
Slide 3: A Rare Company
A Rare Company A unique story in biotech with significant revenue growth and profitability First Two- 10-15% 50-65% First Oral Component Therapy Precision for Pompe Disease Medicine for Fabry Disease FY 2025 FY 2025 Galafold Revenue Pombiliti + Opfolda Growth1 Revenue Growth1 $125M Expanded Portfoli
Slide 4: Galafold Continued Growth
Galafold ® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 4
Slide 5: 2025 Galafold Success (as of March 31, 2025)
2025 Galafold Success (as of March 31, 2025) Only approved oral treatment in Fabry disease and standard of care for amenable patients A unique mechanism of action for Fabry patients with amenable variants $104.2M 1Q25 Galafold 69% Revenue +14% 1Q25 Galafold Share of Treated Patient Demand Amenable P
Slide 6: Galafold Performance
Galafold Performance 1Q 2025 Galafold reported revenue of $104.2M (+6% growth at CER) +10-15%1 Quarterly patient starts remains strong: +14% $458M growth in 1Q YoY2 Q4 1Q revenue impacted by ordering patterns and $388M $128M greater than anticipated U.K. rebate $329M $306M Global mix of naïve
Slide 7: Pombiliti + Opfolda
Pombiliti® (cipaglucosidase alfa-atga) + ® Opfolda (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 7
Slide 8: Pombiliti + Opfolda Performance
Pombiliti + Opfolda Performance 1Q 2025 Pombiliti + Opfolda reported revenue of $21.0M (+92% at CER) Strong 1Q sales growth YoY, particularly in the U.S. +50-65%1 – Number of net new patients continues to grow – Increasing depth and breadth of prescribers 1Q 2025 revenue reflected timing of pati
Slide 9: Pombiliti + Opfolda Expansion
Pombiliti + Opfolda Expansion 3 regulatory approvals and up to 10 new launch countries in 2025 Regulatory Regulatory approvals anticipated in 2025: Recently approved in Australia and Canada Regulatory approval in Japan anticipated in 2025 AUSTRALIA CANADA JAPAN Combined ~150-200 people 18+ livin
Slide 10: Supply Chain
Supply Chain Ensuring access to our two medicines through supply chain planning Limited Tariff Impact Diversifying Supply Chain Anticipate no material impact to P&L or business New commercial manufacturing and supply services operations in 2025 of any of the proposed tariffs: agreement in place
Slide 11: Pombiliti + Opfolda Body of Evidence
Pombiliti + Opfolda Body of Evidence Growing number of abstracts, manuscripts, and case studies supporting Pombiliti + Opfolda differentiation Clinical Trials & Long-Term Data Long-term Phase 1/2 open-label safety and efficacy study (ATB200-02) 104-week Phase 3 open-label extension study of effi
Slide 12: DMX-200
DMX-200 Potential first-in-class investigational small molecule for the treatment of FSGS in the U.S. 12
Slide 13: Exclusive U.S. License Agreement with Dimerix
Exclusive U.S. License Agreement with Dimerix Deal adds significant value to Amicus today and aligns with Amicus strategy to leverage our rare disease commercial infrastructure with promising late-stage program 1 Focal Segmental Glomerulosclerosis (FSGS) is a rare and fatal kidney disease1 that aff
Slide 14: DMX-200 Transaction Summary
DMX-200 Transaction Summary License agreement is heavily weighted to mutually beneficial success-based milestones Upfront investment of $30M paid with cash on hand Up to $560M in potential success-based milestone payments Up to $75M in development & regulatory milestones until FDA approval of DMX-
Slide 15: Focal Segmental Glomerulosclerosis (FSGS) is a rare disease leading to irreversible kidney damage
Focal Segmental Pathogenic Feedback Glomerulosclerosis (FSGS) Loop in FSGS is a rare disease leading to DMX-200 irreversible kidney damage Existing blood pressure specifically blocks kidney medication targets inflammatory signaling angiotensin receptor blocker (ARB) lowers Kidney vessels have to wor
Slide 16: Dimerix has built a strong body of evidence with DMX-200 in FSGS
Dimerix has built a strong body of evidence and made significant clinical and regulatory progress with DMX-200 in FSGS Precision therapy to disrupt the pathogenic monocyte-driven inflammatory feedback MOA loop in the kidney of patients with FSGS Positive efficacy signals and well-tolerated across st
Slide 17: DMX-200 Phase 3 Clinical Trial in FSGS
DMX-200 Phase 3 Clinical Trial in FSGS FDA aligned on proteinuria endpoint for approval; 185 patients already randomized/dosed to date A randomised, double-blind, multi-center, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Background Phase 3 Trial Timel
Slide 18: Corporate Outlook
Corporate Outlook Delivering on our mission for patients and shareholders 18
Slide 19: Q1 2025 Select Financial Results
Q1 2025 Select Financial Results Q1 2025 revenue of $125M, up 15% at CER and non-GAAP net income of $9.0M Q1’25 Mar. 31, 2025 Mar. 31, 2024 (in thousands, except per share data) Net product sales $ 125,249 $ 110,403 Cost of goods sold 11,698 13,567 GAAP operating expenses 121,503 124,557 Non-GAAP op
Slide 20: FY 2025 Financial Guidance
FY 2025 Financial Guidance FY 2025 Financial Guidance1 Previous Guidance Updated Guidance Total Revenue Growth1 17% to 24% 15% to 22% Galafold Revenue Growth1 10% to 15% 10% to 15% FY 2025 Revenue Sensitivity Given the proportion of Amicus revenue ex-US Pombiliti + Opfolda Revenue Growth1 65% to 85%
Slide 21: 2025 Strategic Priorities
2025 Strategic Priorities Deliver total revenue growth of 15-22% at CER1 Double-digit Galafold® revenue growth of 10-15% at CER1 Pombiliti®+ Opfolda® revenue growth of 50-65% at CER1 Advance ongoing studies in Fabry, Pompe and now FSGS Deliver positive GAAP net income during H2 2025 21 1 CER: Consta
Slide 22: A Rare Company
A Rare Company A unique story in biotech with significant revenue growth and profitability Surpassing $1B in Total Sales Double-digit in 2028 Leverageable Revenue Rare Disease Growth Infrastructure Two Approved Self- Therapies Sustainable Company and One Late Stage Growing Free Phase 3 Program Cash
Slide 23: Appendix
Amicus Therapeutics Appendix
Slide 24: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures 24
Slide 25: Reconciliation of Non-GAAP Financial Measures (Cont’d)
Reconciliation of Non-GAAP Financial Measures (Cont’d) 25
Slide 26: Exchange Rates
Exchange Rates Currency Average Rates FX Rates Q1 2024 Q1 2025 Variance USD/EUR 1.086 1.052 (3.1%) USD/GBP 1.268 1.259 (0.7%) USD/JPY 0.007 0.007 (2.7%) 26
Slide 27: Rare Disease Pipeline
Rare Disease Pipeline INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FA B R Y D I S E A S E Galafold® (migalastat) Fabry Genetic Medicines POMPE DISEASE Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Pompe Genetic Medicines RARE KIDNEY DISEASE DMX-200 in Foca